Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given “Neutral” Rating at Wedbush

Wedbush reaffirmed their neutral rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research note published on Friday,RTT News reports. Wedbush currently has a $4.00 price target on the stock.

A number of other analysts also recently issued reports on ZNTL. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Guggenheim dropped their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Zentalis Pharmaceuticals has an average rating of “Hold” and a consensus price target of $10.00.

Zentalis Pharmaceuticals Stock Performance

Zentalis Pharmaceuticals stock opened at $2.22 on Friday. The business has a 50-day simple moving average of $3.05 and a 200 day simple moving average of $3.34. Zentalis Pharmaceuticals has a 52 week low of $2.13 and a 52 week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.36. Analysts forecast that Zentalis Pharmaceuticals will post -2.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ZNTL. Erste Asset Management GmbH purchased a new stake in shares of Zentalis Pharmaceuticals during the third quarter valued at approximately $37,000. Paloma Partners Management Co purchased a new stake in Zentalis Pharmaceuticals during the 3rd quarter valued at $37,000. Aigen Investment Management LP purchased a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at about $41,000. Capstone Investment Advisors LLC bought a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at about $48,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Zentalis Pharmaceuticals by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after purchasing an additional 5,333 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.